Biopharmaceutical Stocks Come Roaring Back After Q1 Correction
Most Stocks Bottomed in April -We are Currently in Rally Mode
The biotech sector is up 18% YTD as tracked by most popular ETFs (FBT,IBB,XBI). After a vicious sell-off from the February bubble the biotech sector bottomed in April and has climbed slowly t within 5% of Q1 highs. However many speculative mid and small caps have not recovered and are more than 50% lower. In this review we will cover our biopharmaceutical focus stocks.
- Our top ETF pick FBT ($84.17) is up 21.7%. Use FBT to overweight your portfolio.
- Our Top Five Winners YTD are : Achillion (ACHN) up 124%, Albany Molecular (AMRI) up 111%, Vertex (VRTX) up 29%, Alkermes (ALKS) up 27.3% and Alexion (ALXN) up 22.5%.
- Our Top Three Losers YTD are : Immunogen (IMGN) down 18,5%, Pharmacyclics (PCYC) down 15.3% and Ariad (ARIA) down 6.3%.
- We recommended two approaches to life science investing. Buy an ETF and a fund or buy a portfolio of stocks with weighting toward large caps. Our large cap portfolio of 8 stocks is up 14% YTD.
For full list of Rayno Life Science stocks see links provided here or Seeking Alpha post.